Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma Nicole L. FranceHannah A. Blair Adis Drug Evaluation Open access 18 January 2024 Pages: 115 - 123
Pemigatinib: A Review in Advanced Cholangiocarcinoma James E. Frampton Adis Drug Evaluation 11 January 2024 Pages: 107 - 114
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer Yu SunakawaYasutoshi KubokiTakayuki Yoshino Original Research Article Open access 09 January 2024 Pages: 59 - 69
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma Eloïne BestionMadani RachidPhilippe Halfon Original Research Article 22 December 2023 Pages: 95 - 106
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea Yeokyeong ShinBo Hyun MoonChanghoon Yoo Original Research Article 18 December 2023 Pages: 41 - 49
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis Brigida Anna MaioranoUgo De Giorgithe MeetURO group Correction Open access 09 December 2023 Pages: 127 - 127
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast Xiuning LeEric NadlerJohn Victor Heymach Correction Open access 09 December 2023 Pages: 125 - 125
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors Serafina MartellaMarco Maria AielloMichele Porcu Review Article 08 December 2023 Pages: 13 - 28
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis Ming-Yu LienTzer-Zen HwangMeng-Che Hsieh Original Research Article 02 December 2023 Pages: 71 - 79
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer Simon FungYahiya Y. Syed Correction Open access 29 November 2023 Pages: 129 - 129
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis Brigida Anna MaioranoUgo De Giorgithe MeetURO group Systematic Review Open access 22 November 2023 Pages: 1 - 11
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study) Estelle DhamelincourtRenaud DescourtFlorian Guisier Original Research Article 15 November 2023 Pages: 905 - 914
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma Alexandr PoprachIgor KissTomas Buchler Original Research Article 13 November 2023 Pages: 893 - 903
Durvalumab: A Review in Advanced Biliary Tract Cancer Simon FungYahiya Y. Syed Adis Drug Evaluation Open access 09 November 2023 Pages: 965 - 972
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer Lauren C. BylsmaXerxes PundoleAnne-Marie C. Dingemans Systematic Review Open access 06 November 2023 Pages: 821 - 835
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers Marine MarchalVincent LeroyAlexis B. Cortot Original Research Article Open access 03 November 2023 Pages: 927 - 939
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status Kenji MorimotoTadaaki YamadaKoichi Takayama Original Research Article 30 October 2023 Pages: 915 - 925
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast Xiuning LeEric NadlerJohn Victor Heymach Correction Open access 27 October 2023 Pages: 991 - 991
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Albiruni R. Abdul RazakHung-Ming WangJean-Pierre Delord Original Research Article Open access 25 October 2023 Pages: 853 - 868
Back to the Bench: Unveiling the Tissue Context is Crucial to Enhance the Efficacy of Agnostic Therapies in Oncology Alessandro OttaianoFrancesco SabbatinoGuglielmo Nasti Commentary 21 October 2023 Pages: 819 - 820
Ivosidenib: A Review in Advanced Cholangiocarcinoma James E. Frampton Adis Drug Evaluation 19 October 2023 Pages: 973 - 980
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators Francesco VoltaSilvia La MonicaRoberta Alfieri Original Research Article Open access 19 October 2023 Pages: 953 - 964
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma Ning WangZhenxian MoWenyu Li Original Research Article 19 October 2023 Pages: 941 - 952
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China Minmin ZhaoShanhu QiuYang Shen Original Research Article Open access 17 October 2023 Pages: 869 - 883
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast Xiuning LeEric NadlerJohn Victor Heymach Commentary Open access 04 October 2023 Pages: 807 - 817
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma Connie Kang Adis Drug Evaluation 03 October 2023 Pages: 981 - 989
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer Vivian PeirceMichael PaskowSukhvinder Johal Review Article Open access 26 September 2023 Pages: 837 - 852
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience Danilo De NovellisRaffaele FontanaCarmine Selleri Original Research Article Open access 25 September 2023 Pages: 885 - 892
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences Jacqueline C. BarrientosAyed O. AyedJing-Zhou Hou Original Research Article Open access 20 September 2023 Pages: 727 - 734
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer Arnold Lee Correction Open access 16 September 2023 Pages: 801 - 801
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1 Xin MiaoLiviawati S. WuSuzette Girgis Original Research Article Open access 15 September 2023 Pages: 667 - 684
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients Scott JewSean BujarskiJames R. Berenson Original Research Article 08 September 2023 Pages: 735 - 747
Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer Amandine GouverneurClélia FavaryPernelle Noize Original Research Article 08 September 2023 Pages: 717 - 726
Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study Seiichiro MitaniYosuke KitoHisato Kawakami Original Research Article 05 September 2023 Pages: 707 - 715
Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma Jiayu WangDana Al-MajidJoshua D. Smith Review Article 04 September 2023 Pages: 643 - 655
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial Robert J. MotzerPaul RussoAxel Bex Summary of research Open access 02 September 2023 Pages: 639 - 641
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis Devon J. BoyneDavid E. DaweWinson Y. Cheung Original Research Article 01 September 2023 Pages: 697 - 705
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Lan-Hsi LinMohammad GhasemiAndrew K. L. Goey Original Research Article 26 August 2023 Pages: 685 - 695
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study Kenji MorimotoTadaaki YamadaKoichi Takayama Original Research Article 23 August 2023 Pages: 657 - 665
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich Danmei ZhangKlara DormanC. Benedikt Westphalen Original Research Article Open access 18 August 2023 Pages: 767 - 776
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer Arnold Lee Adis Drug Evaluation Open access 05 August 2023 Pages: 793 - 800
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6) Hanno M. WitteJörg RiedlNiklas Gebauer Original Research Article Open access 24 July 2023 Pages: 749 - 765
FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications Marjorie E. Zettler Original Research Article 21 July 2023 Pages: 777 - 792
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer Angela DeMicheleNicholas RobertLynn McRoy Original Research Article Open access 10 July 2023 Pages: 543 - 558
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study Matteo SantoniFrancesco MassariCamillo Porta Original Research Article 27 June 2023 Pages: 559 - 570
Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study Erica M. StormDimitrios MakrakisAli Raza Khaki Original Research Article 26 June 2023 Pages: 601 - 610
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Nan ZhengYimin ZhangLi Li Original Research Article 23 June 2023 Pages: 625 - 636
Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours Chih-Chieh YenYu-Min YehChia-Jui Yen Original Research Article Open access 22 June 2023 Pages: 611 - 623
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Michelle WangShadera SlatterVivek A. Rudrapatna Original Research Article Open access 21 June 2023 Pages: 571 - 583